Literature DB >> 15523322

Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial.

Sandeep R Das1, Mark H Drazner, Clyde W Yancy, Lynne W Stevenson, Bernard J Gersh, Daniel L Dries.   

Abstract

BACKGROUND: Emerging data suggest that diabetes mellitus is a risk factor for the progression of established heart failure only in those patients with ischemic cardiomyopathy. Whether diabetes mellitus is a risk factor for the progression from asymptomatic left ventricular systolic dysfunction to symptomatic heart failure in patients with left ventricular dysfunction of an ischemic cause is not known.
METHODS: We performed a retrospective analysis of 2821 patients with asymptomatic left ventricular systolic dysfunction from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. We used adjusted survival analysis to examine the effects of ischemic heart disease and diabetes mellitus on 3 prespecified study end points: (1) development of heart failure (HF) symptoms, (2) HF hospitalization, and (3) death or development of symptoms.
RESULTS: There is a statistically significant interaction between the cause of left ventricular systolic dysfunction and diabetes mellitus on the risk of development of heart failure symptoms (P = .020). Patients with ischemic cardiomyopathy and diabetes had an increased risk of progression to symptomatic heart failure (HR = 1.56, P < .001), hospitalization for heart failure (HR = 2.16, P < .001), and death or development of symptoms (HR = 1.50, P < .001), compared with patients with ischemic cardiomyopathy without diabetes. In contrast, diabetes was not associated with an increased risk of reaching these end points in patients with nonischemic cardiomyopathy.
CONCLUSIONS: Diabetes mellitus is a risk factor for the progression from asymptomatic left ventricular systolic dysfunction to symptomatic heart failure, but this risk appears to be confined to those patients with ischemic cardiomyopathy.

Entities:  

Mesh:

Year:  2004        PMID: 15523322     DOI: 10.1016/j.ahj.2004.04.019

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  18 in total

1.  Effectiveness of cardiac resynchronization therapy in diabetic patients with ischemic and nonischemic cardiomyopathy.

Authors:  Jenie George; Alon Barsheshet; Arthur J Moss; David Martin; Gregory Ouellet; Scott McNitt; Ilan Goldenberg
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-01       Impact factor: 1.468

Review 2.  Update on Echocardiographic Assessment in Diabetes Mellitus.

Authors:  Ying Wang; Thomas H Marwick
Journal:  Curr Cardiol Rep       Date:  2016-09       Impact factor: 2.931

3.  The Bi-directional Impact of Two Chronic Illnesses: Heart Failure and Diabetes - A review of the Epidemiology and Outcomes.

Authors:  Patrick Campbell; Selim Krim; Hector Ventura
Journal:  Card Fail Rev       Date:  2015-04

4.  Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in utero.

Authors:  W Todd Cade; Alan D Waggoner; Sara Hubert; Melissa J Krauss; Gautam K Singh; E Turner Overton
Journal:  AIDS       Date:  2012-10-23       Impact factor: 4.177

Review 5.  Diabetic cardiovascular disease: getting to the heart of the matter.

Authors:  Linda R Peterson; Clark R McKenzie; Jean E Schaffer
Journal:  J Cardiovasc Transl Res       Date:  2012-05-26       Impact factor: 4.132

Review 6.  Diabetes and heart failure in the post-myocardial infarction patient.

Authors:  Jerry D Estep; David Aguilar
Journal:  Curr Heart Fail Rep       Date:  2006-12

7.  Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).

Authors:  Christian Torp-Pedersen; Marco Metra; Andrew Charlesworth; Phillip Spark; Mary Ann Lukas; Philip A Poole-Wilson; Karl Swedberg; John G F Cleland; Andrea Di Lenarda; Willem J Remme; Armin Scherhag
Journal:  Heart       Date:  2007-01-19       Impact factor: 5.994

8.  Abnormal myocardial perfusion and risk of heart failure in patients with type 2 diabetes mellitus.

Authors:  Marcelo Utrera-Lagunas; Arturo Orea-Tejeda; Lilia Castillo-Martínez; Karla Balderas-Muñoz; Candace Keirns-Davis; Sarahi Espinoza-Rosas; Néstor Alonso Sánchez-Ortíz; Gabriela Olvera-Mayorga
Journal:  Exp Clin Cardiol       Date:  2013

Review 9.  Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.

Authors:  Ersilia M DeFilippis; Michael M Givertz
Journal:  Curr Heart Fail Rep       Date:  2016-06

Review 10.  Diabetic cardiomyopathy.

Authors:  Ankur A Karnik; Anjali V Fields; Richard P Shannon
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.